Trial intelligence / Profile preview

Fluticasone furoate nasal spray for uncomplicated acute rhinosinusitis

2009-015014-22Phase 2Completed

Sponsor
GSK
Start
Nov 2009
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of fluticasone in acute rhinosinusitis (ARS) (3 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in daily major symptom score over the entire treatment period. Started Nov 2009; status: completed.

02

Drugs

fluticasone
03

Conditions

acute rhinosinusitis (ARS)

Beyond the preview

Go deeper on 2009-015014-22.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-015014-22.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call